News

Dazodalibep’s Benefits Seen In 2nd Sjögren’s Patient Group

Investigational therapy dazodalibep significantly eased symptom burden in people with Sjögren’s syndrome who have moderate-to-severe symptoms, but minimal systemic disease activity, meeting the goal of Horizon Therapeutics‘ Phase 2 clinical trial. Horizon previously announced the trial also met its other main goal of reducing disease activity in…

Risk of Heart Failure Increased More Than 40% in Primary Sjögren’s

People with primary Sjögren’s syndrome (PSS) are at an increased risk of developing heart failure, heart attack, stroke, and other cardiovascular health problems compared with the general population, a new study reports. “The findings from our analysis could potentially have important clinical implications,” the researchers wrote. “Despite a low…